Natural killer (NK) cells have been shown to participate in graft versus leukemia (GvL) effects after haploidentical transplantation, especially if NK alloreactivity occurs due to incompatibilities between killer immunoglobulin-like receptors on donor NK cells and human leukocyte antigen (HLA) ligands on recipient cells. [1] [2] [3] To take advantage of these effects immediately after transplantation, depletion of unwanted T and B cells (CD3/CD19 depletion) is currently used to produce grafts containing not only stem cells but also high numbers of NK cells. 4 Moreover, additional NK cell infusions represent an interesting option for further immunotherapy and have been already used to treat or prevent disease relapse. 5, 6 As cytokine stimulation strongly increases NK cell-mediated antileukemic activity, we investigated the use of haploidentical, interleukin (IL)-15-stimulated CD3/CD19-depleted grafts in combination with induction and low-dose maintenance chemotherapy for treatment of post-transplant relapse.
Eight patients received IL-15-stimulated stem-cell boosts on a compassionate level of use after providing informed consent. Granulocyte-colony stimulating factor-mobilized peripheral blood stem cells were depleted of CD3 þ and CD19 þ cells with the ClinicMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany) as published earlier. 4 CD3/19 À cells (comprising stem cells, NK cells and monocytes) were diluted in RPMI medium containing 10% human AB serum, 2 mM L-glutamine and 10 ng/ml IL-15 under GMP (good manufacturing practice) conditions. Cells were incubated overnight for at least 12 h in tissue culture flasks at a concentration of 10 Â 10 6 cells/ml. Afterwards, cells were washed four times in 0.9% NaCl. Production was performed under the approval of the local authorities according to y4b of the German drug law (AMG).
Grafts were analyzed by flow cytometry for CD34 þ progenitors, CD69 þ -activated NK cells and for residual T and B cells and monocytes (BD, Heidelberg, Germany, Table 1 ). NK cell chimerism in patient 3 was analyzed with a HLA-A2 antibody (One Lambda, Los Angeles, CA, USA). Cytolytic activity of NK cells was tested in a 2-h BATDA-release assay (Perkin Elmer, Waltham, MA, USA) against K562 cells. BrdU (Bromodeoxyuridine)-assay was done as described by the manufacturer (Roche, Basel, Switzerland) after stimulation with phytohemagglutinin (PHA), IL-2, (100 international units), muronomab-CD3 (Orthoclone OKT-3, pokeweed mitogen (PWM) and concanavalin A (ConA). Thymidine assay was conducted as described earlier. 7 First, we tested the NK cell activity of CD3/19-depleted cells after cytokine stimulation in vitro. IL-15-stimulated CD3/19 À cells had a significantly higher lytic activity than that of unstimulated cells (61% versus 25%) or IL-2-stimulated cells (61% versus 41%). A combination of IL-2 and IL-15 did not further increase lysis (Figure 1a) . No effect was seen with IL-18, whereas the effect of IL-12 was similar to that of IL-2. On the basis of these findings we established an ex vivo stimulation protocol under GMP conditions. Altogether 11 procedures were done. 
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Abbreviations: AML, acute myeloid leukemia; B-ALL, acute B-cell lymphoblastic leukemia; cALL, common acute lymphoblastic leukemia; CNS, central nervous system; CR, complete remission; IL, interleukin; NB IV, neuroblastoma stage 4; NR, non-remission; pat. no., patient number (patients 1, 2 and 7 received two boosts each); PD, progressive disease; s.c, subcutaneous; SCT, stem cell transplantation; T-ALL, T-cell acute lymphoblastic leukemia. All patients relapsed 80-330 days after last stem cell transplantation and received a protocol with three components: (1) low-dose induction chemotherapy (adapted the underlying disease), followed if possible by an intensification; (2) infusion of IL-15-stimulated boosts followed by a waiting period of at least 4 weeks in order not to hamper cytotoxic effects or proliferation; (3) maintenance chemotherapy. Induction: Vcr showed only low cytotoxic activity with a significant increase after stimulation (t-test, P ¼ 0.001, Figure 1b) . BrdU assays showed no difference in proliferation responses to T-cell mitogens, indicating a low risk of graft-versus-host disease (GvHD), but showed a significant difference in proliferation responses to IL-2, which may be explained by a synergistic effect of IL-2 and IL-15 on NK cell proliferation (Figure 1c) . Thus, additional incubation of IL-15-prestimulated cells with IL-2 resulted in a significantly higher response than incubation of unstimulated cells with IL-2. The same results were found in a 3 H-thymidine incorporation assay with irradiated allogeneic stimulator cells or PHA (Figure 1d) .
All patients experienced a relapse 80-330 days post transplant. They received induction chemotherapies adapted to the underlying disease and clinical condition (Table 1) . At 2-7 days after therapy, stimulated boosts were infused over 1 h (mean 50 Â 10 6 NK and 2.2 Â 10 6 stem cells/kg). Monitoring comprised measurement of blood pressure, pulse, oxygen saturation, temperature and clinical examinations. No acute side effects were observed, in particular no signs of cytokine release or allergic reactions. After a median time interval of 4 weeks, maintenance chemotherapy was added in 7 of 8 patients (Table 1) . Seven patients received stimulated grafts from the same haploidentical donor from whom they had been transplanted previously. Patient 3 received a haploidentical stimulated graft after matched unrelated donor transplantation. We observed an expansion of the HLA-disparate NK cells, with a maximum at day 10. Afterwards, haploidentical NK cells were rejected stepwise and disappeared completely after 30 days in this patient. Interestingly, autologous NK cells from the patient paralleled the course of the haploidentical NK cells, indicating a stimulating effect of the graft infusion also on the autologous cells (Figure 2c ). This effect might be caused by cotransfused myeloid cells, which should be able to present membrane-bound IL-15 also to autologous NK cells, and therefore might enhance proliferation-inducing endogenous IL-15 levels in vivo. In the other patients, transfused NK cells could not be traced by HLA flow cytometry. However, staining of NK cells with CD69 showed an increase in CD69 þ NK cells in the first week after infusion (Figure 2b) . All patients showed a fast hematopoietic reconstitution. Between 15-30 days after boosting,
þ lymphocyte counts were similar (or even higher) to those before start of chemotherapy (Figure 2a) . Seven of eight patients relapsed during maintenance therapy. Three patients received a second donation of IL-15-stimulated grafts, with another preceding induction chemotherapy. Second maintenance therapies were added after 4 weeks in all three patients.
Three other patients received no further therapy. One patient proceeded after reinduction to third transplantation. Finally, all eight patients died from subsequent relapse/progression. No therapy-related mortality occurred. Median overall survival (day 0 ¼ date of post-transplant relapse) was 194 days (mean 234, Table 1 ).
Donor NK infusions have already been used after haploidentical transplantation. 8 These products were obtained by a two-step Cytotoxic activity against K562 was tested before infusion into the patients and compared with the lysis obtained without stimulation (n ¼ 9). Unstimulated products showed only low cytotoxic activity, with a significant increase after stimulation (t-test, P ¼ 0.001). (c) Proliferative capacity of CD3/19-depleted boosts before and after ex vivo IL-15 incubation was tested in BrdU assays after stimulation with additional cytokines or mitogens (n ¼ 4). After ex vivo IL-15 incubation, a significant increase in response to IL-2 (P ¼ 0.032) but no response to T-cell mitogens was observed. (d) Thymidine uptake after stimulation with irradiated allogeneic feeder cells and mitogens/cytokines. Only minimal uptake was observed with feeder cells or PHA (due to absence of alloreactive T cells), whereas high uptake was found after stimulation with IL-2 and to a lower extent with additional IL-15.
isolation of NK cells from additional unstimulated leukapheresis products. In contrast, the aim of our approach was not to obtain a pure population of NK cells but to combine the donation of both stem cells and stimulated effector cells. As bone marrow insufficiency occurred in all patients after induction chemotherapy, the stem cell component of our IL-15-stimulated grafts was of great clinical importance: a fast hematopoietic recovery (including T cells) could be observed and enabled further maintenance therapy. Thus, with our approach no additional leukapheresis was necessary and depletion of unwanted cells was done in one step. IL-15 was more potent in short-time stimulation compared with IL-2, and administration of those cell products was well tolerated without any acute and late side effects, especially without induction of GvHD.
Miller et al. 5 used haploidentical CD3-depleted leukapheresis products after overnight stimulation with IL-2 in a non-transplant setting, and demonstrated that NK cells persisted for around 28 days in most patients. In our patients we observed a comparable duration of donor NK cell expansion, which might be further increased by in vivo IL-2 administration.
In summary, the major goals of this trial were to demonstrate that infusions of IL-15-stimulated grafts are safe and feasible even in the haploidentical setting and lead to a fast hematopoietic recovery, with detectable and activated CD69 þ NK cells. Combinations with different chemotherapies were possible in the vulnerable posttransplant period and contributed to prolonged survival. However, no firm conclusions can be drawn about the GvL or graft versus tumor effect of the cell infusions themselves to date. 
